Dr. Anishka D'Souza

Claim this profile

Los Angeles County-USC Medical Center

Studies Bladder Cancer
Studies Urethral Cancer
5 reported clinical trials
11 drugs studied

Area of expertise

1

Bladder Cancer

Anishka D'Souza has run 3 trials for Bladder Cancer. Some of their research focus areas include:

Stage IV
Stage III
FGFR3 positive
2

Urethral Cancer

Anishka D'Souza has run 3 trials for Urethral Cancer. Some of their research focus areas include:

Stage IV
Stage III
FGFR3 positive

Affiliated Hospitals

Image of trial facility.

Los Angeles County-USC Medical Center

Image of trial facility.

USC / Norris Comprehensive Cancer Center

Clinical Trials Anishka D'Souza is currently running

Image of trial facility.

Radium-223 + M3814 + Avelumab

for Prostate Cancer

This phase I/II trial studies the best dose of M3814 when given together with radium-223 dichloride or with radium-223 dichloride and avelumab and to see how well they work in treating patients with castrate-resistant prostate cancer that had spread to other places in the body (metastatic). M3814 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radioactive drugs, such as radium-223 dichloride, may carry radiation directly to tumor cells and not harm normal cells. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This study is being done to find out the better treatment between radium-223 dichloride alone, radium-223 dichloride in combination with M3814, or radium-223 dichloride in combination with both M3814 and avelumab, to lower the chance of prostate cancer growing or spreading in the bone, and if this approach is better or worse than the usual approach for advanced prostate cancer not responsive to hormonal therapy.

Recruiting

1 award

Phase 1 & 2

Image of trial facility.

Immunotherapy + Targeted Therapy

for Genitourinary Cancers

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.

Recruiting

1 award

Phase 2

21 criteria

More about Anishka D'Souza

Clinical Trial Related

7 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Anishka D'Souza has experience with

  • Atezolizumab
  • Eribulin Mesylate
  • Cabozantinib S-malate
  • Ipilimumab
  • Nivolumab
  • Avelumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Anishka D'Souza specialize in?

Is Anishka D'Souza currently recruiting for clinical trials?

Are there any treatments that Anishka D'Souza has studied deeply?

What is the best way to schedule an appointment with Anishka D'Souza?

What is the office address of Anishka D'Souza?

Is there any support for travel costs?